Mineralys Therapeutics, Inc.
NASDAQ:MLYS · NASDAQ Global Select
+$0.37 today
Vol 3.33M · Avg 1.48M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-23.9%
avg 15.0%
ROIC
-26.4%
avg -137.7%
ROA
-23.4%
avg -94.9%
Analysis
ROA is currently the strongest return metric at -23.4% versus its period average of -94.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jon Congleton | President, Chief Executive Officer & Director | $1.11M | — | 63 | $689,321.00 | 1.04% |
David Rodman | Chief Medical Officer | $881,798.00 | — | 71 | $57,095.00 | 0.09% |
Adam Scott Levy | Chief Financial Officer & Secretary | $880,190.00 | — | 48 | $53,300.00 | 0.08% |
Brian Taylor Slingsby | Founder & Executive Director | $78,000.00 | — | 49 | $7.91M | 11.93% |
Danielle Mahoney | Senior Vice President of Quality Assurance | — | — | — | — | — |
Michael Tortorici | Senior Vice President of Translational Medicine | — | — | — | — | — |
Tiffany Ellen Burt | Senior Vice President of Medical Affairs | — | — | — | — | — |
Eric J. Warren | Chief Commercial Officer | — | — | 54 | $38,400.00 | 0.06% |
Jeffrey A. Munsie | Chief Legal Officer | — | — | 49 | — | — |
Robert McKean | Senior Vice President of CMC | — | — | — | — | — |
Jessica Ibbitson | Executive Vice President of Operations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$8.76M
Sells
67
$77.83M
Net Sentiment
$69.07M
Net selling
Most Active
Rodman David Malcom
33 transactions
1–10 of 69
Analysis
Insiders reported 2 buys worth $8.76M and 67 sells worth $77.83M over the last 12 months. That adds up to net selling of $69.07M. Rodman David Malcom was the most active insider with 33 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Cidara Therapeutics, Inc.
CDTX
$5.61B
Scholar Rock Holding Corporation
NASDAQ:SRRK
$5.56B
Apellis Pharmaceuticals, Inc.
APLS
$5.25B
Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRX
$3.84B
Beam Therapeutics Inc.
NASDAQ:BEAM
$3.40B
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
$2.92B
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
$2.78B
Zai Lab Limited
NASDAQ:ZLAB
$2.06B
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
$2.00B
Recursion Pharmaceuticals, Inc.
NASDAQ:RXRX
$1.42B
Who manages MLYS?
Mineralys Therapeutics, Inc. (MLYS) lists 11 active executives. The top listed executive is Danielle Mahoney, Senior Vice President of Quality Assurance.
Are MLYS insiders buying or selling?
Recent insider activity shows net selling of $58.96M.
Explore More
Continue the stock analysis
Jump to another research area for this company.